Navigation Links
Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
Date:12/31/2007

CARLSBAD, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has authorized a Phase 2a clinical trial evaluating RDEA806, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), in patients with human immunodeficiency virus (HIV), the causative agent of AIDS.

"There is a clear unmet need for new NNRTIs that have the potential for a lower incidence of neuropsychiatric adverse effects, a high barrier to resistance, activity against resistant strains and the ability to be combined with other therapeutic agents," said Barry Quart, PharmD, President and CEO of Ardea Biosciences. "We believe that RDEA806 has the potential to offer a new option for patients with HIV and are excited to move this novel compound into Phase 2 clinical testing. We expect to obtain results from this trial in the first quarter of 2008."

The Phase 2a randomized, double-blind, proof-of-concept trial will be conducted in multiple European academic medical centers. The trial will evaluate the antiviral activity, pharmacokinetics, safety and tolerability of once daily and twice daily dose regimens of RDEA806 versus placebo in HIV-1 positive patients who are naive to antiretroviral treatment. The primary efficacy endpoint is the change from baseline in plasma viral load.

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potential for potent antiviral activity against a wide range of HIV vira
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... with increased inflammation, including those receiving cytokines for ... depression. For example, a 6-month treatment course of ... causes depression in approximately 30% of patients. ... fish oil, have a long list of health ... and reducing triglyceride levels. These nutritional compounds are ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining ... , Senior citizens can qualify for affordable term life ... who are over 50 years old. Some term life ... examination. , Term life insurance with a simplified issue ... Having life insurance during retirement is important for covering ...
(Date:10/1/2014)... 2014 Bedros Keuilian is not only ... fitness boot camps, he’s also considered the leading expert ... sold out business summits, a line of high-demand fitness ... a recent Spike TV reality show to his name. ... the time for personal trainers and fitness business owners ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... A clinical trial in Cambodia has found it possible ... very weak immune systems and newly diagnosed tuberculosis (TB) ... treatment, rather than waiting eight weeks, as has been ... Institute of Allergy and Infectious Diseases (NIAID), part of ...
... July 22 Adult circumcision has been proposed as a ... study by the University of Pittsburgh Graduate School of ... suggests it would have a very small effect on reducing ... thought to reduce the risk of HIV transmission by removing ...
... insulin resistance and the action of diabetes drugs such ... improved medications that are more selective and safer, say ... Institute. "Our findings strongly suggest that good and ... designing second-generation drugs that focus on the newly uncovered ...
... College Park, MD (July 20, 2010) -- Eighty years ago, ... of metabolism, but the idea went out of vogue. Now, ... cancer and other common diseases. Metabolism is a highly connected ... pathways. Such parallelism can mask how genes are linked ...
... Cancer surgery wreaks havoc on a body,s immune system and ... of those who undergo surgery for tumor removal experience a ... of the body. A new clinical approach being ... the key to making cancer operations more successful. Prof. Shamgar ...
... group of patients at one of the nation,s largest ... who have previously refused colorectal cancer screening, are willing ... but not willing to pay for the exam themselves ... in the August issue of the American Journal ...
Cached Medicine News:Health News:NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 2Health News:Scientists find unsuspected molecular link between obesity and insulin resistance 3Health News:A new drug treatment to close the window on colon cancer 2Health News:Lack of insurance coverage remains obstacle to wider colorectal cancer screening with CT colonography 2
(Date:9/30/2014)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Officer, will present at the Stem Cell Meeting on ... 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... , Sept. 30, 2014 STUDY OBJECTIVES ... study is to provide an overview of the ... for protein drugs/therapeutics. The key objective is to ... protein drugs as an important tool in the ... present and future strategies within the protein therapeutics ...
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Provides an approach to treatment ... a pressure range to 25 ... to treat patients with severe ... features integrated humidification and built-in ...
... specifically designed for monitoring the performance ... for separation and quantification of cholesterol ... in patient serum samples. Liposure is ... and A (IDL), LDL subfractions, HDL ...
This control is intended for monitoring cell counts in patient cerebrospinal fluid samples, performed manually using a hemocytometer. Spinalscopics is fortified to target levels with purified chemica...
... Ammonia/Alcohol Control is intended ... various ammonia and ethanol assay ... is targeted at clinically significant ... Assay values are provided for ...
Medicine Products: